Angiogenesis and Gene Therapy
Year: 2003
Type: book-chapter
Abstract: Angiogenic growth factors constitute a potentially novel form of therapy for patients with ischemic vascular disease. The feasibility of using recombinant formulations of angiogenic growth factors to augment collateral artery development by stimulation of capillary growth in animal models of myocardial and hind limb ischemia has now been well established. This novel strategy for the treatment of vascular insufficiency, depicted schematically for peripheral vascular disease in Fig. 1, has been termed therapeutic angiogenesis. Studies have suggested that three angiogenic growth factors in particular—acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF)—are sufficiently potent to merit further investigation. In the case of VEGF and aFGF, bioavailability and meaningful angiogenic bioactivity were also shown to be achievable by intramuscular gene transfer, with clinical phase I trials in patients with chronic critical limb ischemia (CLI) cautiously interpreted to support both the strategy of somatic gene therapy and the concept of therapeutic angiogenesis.
Source: Humana Press eBooks
Authors: Iris Baumgartner, Jeffrey M. Isner
Institution: Tufts University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W1831196035